Neurotrope, Inc. Common
NTRP
NTRP was delisted on the 1st of December, 2020.
26 hedge funds and large institutions have $4.9M invested in Neurotrope, Inc. Common in 2018 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
8% more funds holding
Funds holding: 24 → 26 (+2)
57% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 7
61% less capital invested
Capital invested by funds: $12.5M → $4.9M (-$7.64M)
83% less call options, than puts
Call options by funds: $6K | Put options by funds: $36K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NP
NorthRock Partners
Minneapolis,
Minnesota
|
+$433K |
| 2 |
EVM
Eaton Vance Management
Boston,
Massachusetts
|
+$278K |
| 3 |
Renaissance Technologies
New York
|
+$150K |
| 4 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
+$133K |
| 5 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$71.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Cannell & Co
New York
|
-$560K |
| 2 |
Stifel Financial
St. Louis,
Missouri
|
-$483K |
| 3 |
ISL
Ingalls & Snyder LLC
New York
|
-$148K |
| 4 |
Millennium Management
New York
|
-$132K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$121K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$121K | -19,901 | Closed |
|
|
27
Millennium Management
New York
| – | -$132K | -14,928 | Closed |
|
28
Morgan Stanley
New York
| – | -$2.02K | -334 | -89% |
|
NTRP Hedge Fund Activity: Q4 2018 in Review
26 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Neurotrope, Inc. Common (NTRP) for Q4 2018, worth a combined $4.9M — down 61% from $12.5M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new NTRP positions and 3 closed out — a net gain of 2 holders — while 3 added to existing stakes and 7 trimmed.
The largest buyer was NorthRock Partners, opening a new position worth an estimated $433K. The largest seller was Cannell & Co, cutting an estimated $560K.
- 26 institutional investors held Neurotrope, Inc. Common (NTRP) as of Q4 2018, up from 24 in Q3 2018.
- Funds reported $4.9M of Neurotrope, Inc. Common stock for Q4 2018, down 61% quarter-over-quarter.
- 5 funds opened new Neurotrope, Inc. Common positions in Q4 2018 and 3 closed out, a net change of +2 holders.
- The largest Neurotrope, Inc. Common buyer in Q4 2018 was NorthRock Partners, an estimated $433K added.
- The largest Neurotrope, Inc. Common seller in Q4 2018 was Cannell & Co, an estimated $560K sold.
Based on aggregated 13F filings for Q4 2018.